Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F20%3A00534655" target="_blank" >RIV/86652036:_____/20:00534655 - isvavai.cz</a>
Result on the web
<a href="https://www.thno.org/v10p5259.htm" target="_blank" >https://www.thno.org/v10p5259.htm</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.7150/thno.42705" target="_blank" >10.7150/thno.42705</a>

Result language
angličtina
Original language name
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
Original language description
Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30100 - Basic medicine

Project
<a href="/en/project/NV17-30138A" target="_blank" >NV17-30138A: OXPHOS Addiction as a New Hallmark in Cancer: Its Use for Development of Novel, Efficient Cancer Therapy</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)